Monday, June 4, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CTO, Alexander Zhebrak, at the AI in Healthcare Summit, June 7, 2018, organized by Re-Work in Hong Kong.
Mr. Zhebrak's session "Longenesis: Returning the Control over Personal and Medical Data Back to the Individual Using Ai-Driven Blockchain Solutions" will focus on the development of blockchain-based health data escrow which uses AI to store, manage, and trade health data. The presentation will explore how Longenesis platform provides the access for patients to their private health data and ensures a safe, distributed trading of health data giving insights both for patients and healthcare products developers.
"We are very happy to present our work at the AI in Healthcare Summit, which gathers many thought leaders in AI. The topic of AI for Healthcare is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.
AI in Healthcare Summit is gathering key experts in speech and text recognition, neural networks, image classification and machine learning to discover advances in machine learning tools and techniques from the world's leading innovators across industry, academia and the healthcare sector. The summit aims to showcase the opportunities of advancing methods in deep learning and their impact across healthcare and medicine. The event will transpire on June 7-8.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
For further information, images or interviews, please contact:
Official Conference Website: http://www.
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.
The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.
Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Brief company video: https:/